Is NCT06358677 recruiting in Salt Lake City, UT?

Yes, NCT06358677 is currently recruiting participants at its Salt Lake City, UT location. This metastatic solid tumor clinical trial is actively enrolling qualified participants.

How do I join the metastatic solid tumor clinical trial in Salt Lake City?

To join this clinical trial in Salt Lake City, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Salt Lake City clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Metastatic Solid Tumor Clinical Trial in Salt Lake City, UT

About This Metastatic Solid Tumor Study in Salt Lake City

The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.

Sponsor: University of Utah

Who Can Participate

Inclusion Criteria

Participant aged ≥ 18 years

Histologically confirmed solid tumor.

Radiologically confirmed locally advanced or metastatic disease.

Eligible for and willing to receive treatment with panitumumab or cetuximab as standard-of-care.

ECOG Performance Status ≤ 2.

Adequate organ function as defined as: --Hepatic:

Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)

AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN ----Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.

Negative pregnancy test for participants who have not undergone surgical sterilization or shown evidence of post-menopausal status. The following age-specific requirements apply: --\< 50 years of age:

Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and

Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or

Underwent surgical sterilization (bilateral oophorectomy or hysterectomy). --≥ 50 years of age:

Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or

Had radiation-induced menopause with last menses \>1 year ago; or

Had chemotherapy-induced menopause with last menses \>1 year ago; or

Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.2.

Must have recovered from adverse effects of any prior oncologic treatment (e.g. prior surgery, radiotherapy, or other antineoplastic therapy). CTCAE adverse events less than or equal to grade 1 are acceptable. CTCAE adverse events grade 2 or greater may be acceptable as determined by an investigator with appropriate documentation.

Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria

Treatment with an anti-EGFR agent within 90 days of registration.

Pre-existing facial rash that per the treating investigator would preclude the ability to assess response to topical tretinoin.

The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).

Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Systemic active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), or hepatitis C. --Note: Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

Medical, psychiatric, cognitive, or other conditions that may compromise the participant's ability to understand the participant information, give informed consent, comply with the study protocol or complete the study.

Known prior severe hypersensitivity to investigational product or any component in its formulations (CTCAE v5.0 Grade ≥ 3).

Participants taking prohibited medications as described in Section 6.8.2. A washout period of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Salt Lake City?

Yes, this clinical trial (NCT06358677) has an active research site in Salt Lake City, UT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Solid Tumor Treatment Options in Salt Lake City, UT

If you're searching for metastatic solid tumor treatment options in Salt Lake City, UT, this clinical trial (NCT06358677) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Salt Lake City research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced metastatic solid tumor specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic solid tumor clinical trials near you to find additional studies recruiting in your area.

Metastatic Solid Tumor Clinical Trial in Salt Lake City, UT

Expert Care in Salt Lake City

IRB Approved

No-Cost Care

Apply for This Salt Lake City Location

Why Participate?

Simple Process